ternium6k.htm
FORM
6 - K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a - 16 or 15d - 16 of
the
Securities Exchange Act of 1934
As
of 6/3/2009
Ternium
S.A.
(Translation
of Registrant's name into English)
Ternium
S.A.
46a,
Avenue John F. Kennedy – 2nd floor
L-1855
Luxembourg
(352)
4661-11-3815
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or 40-F.
Form 20-F ü Form
40-F
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12G3-2(b) under the Securities Exchange Act of 1934.
Yes
No ü
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
Not applicable
The
attached material is being furnished to the Securities and Exchange Commission
pursuant to Rule 13a-16 and Form 6-K under the Securities Exchange Act of 1934,
as amended.
This
report contains a summary of the resolutions adopted in the annual general
meeting of shareholders of Ternium S.A. held on June 3, 2009.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
TERNIUM
S.A.
By: /s/ Raul
Darderes
Name:
Raul Darderes
Title:
Secretary of the Board of Directors
Dated:
June 3, 2009
Summary
of the resolutions adopted in the Annual General Meeting of Shareholders of
TERNIUM S.A. (the “Company”) held on June 3, 2008 at 46A, avenue John F.
Kennedy, L-1855 Luxembourg, at 2:30 p.m. (C.E.T.) (the “Meeting”)
1) Consideration
of the Board of Directors’ and independent auditor’s reports on the Company’s
consolidated financial statements. Approval of the Company’s consolidated
financial statements as of December 31, 2008 and 2007 and for the years ended
December 31, 2008, 2007 and 2006.
The
Meeting resolved to approve the Company’s consolidated financial statements as
of December 31, 2008 and 2007 and for the years ended December 31, 2008, 2007
and 2006, after due consideration of the reports of the Board of Directors and
the independent auditors on such consolidated financial statements.
2) Consideration
of the Board of Directors’ and independent auditor’s reports on the Company’s
annual accounts. Approval of the Company’s annual accounts as at December 31,
2008.
The
Meeting resolved to approve the Company’s annual accounts as at December 31,
2008, after due consideration of the reports of the Board of Directors and the
independent auditor on such annual accounts.
3) Allocation
of results.
The
Meeting resolved to allocate the net profit of the year ended December 31, 2008
of USD225,455,160.00; to the Company’s retained earnings account.
4) Discharge
to the members of the Board of Directors for the exercise of their mandate
throughout the year ended December 31, 2008.
The
Meeting resolved to discharge all of those who were members of the Board of
Directors during the year ended December 31, 2008, from any liability in
connection with the management of the Company’s affairs during such
year.
5) Election
of the members of the Board of Directors.
The
Meeting resolved that each of Messrs. Mr. Ubaldo Aguirre; Mr. Roberto Bonatti,
Mr. Wilson Nélio Brumer, Mr. Marco Antônio Soares da Cunha Castello Branco; Mr.
Carlos Condorelli, Pedro Pablo Kuczynski; Mr. Adrian Lajous Vargas; Mr. Bruno
Marchettini; Mr. Gianfelice Mario Rocca, Mr. Paolo Rocca and Mr. Daniel Agustin
Novegil be re-appointed as a member of the Board of Directors, each to hold
office until the next annual general meeting of shareholders that will be
convened to decide on the 2009 accounts.
6) Compensation
of the members of the Board of Directors.
The
Meeting resolved that each of the members of the Board of Directors receive an
amount of USD 70,000.00 as compensation for their services during the fiscal
year 2009, and that the Chairman of the Board of Directors receive, further, an
additional fee of USD 280,000.00.
The
Meeting further resolved that the directors who are members of the audit
committee each receive an additional fee of USD50,000, and that the Chairman of
such committee receive, further, an additional fee of USD10,000.
7) Appointment
of the independent auditors and approval of their fees.
The
Meeting resolved to appoint PricewaterhouseCoopers (acting, in connection with
the Company’s annual accounts and annual consolidated financial statements
required under Luxembourg law, through PricewaterhouseCoopers S.àr.l., Réviseur
d'entreprises, and, in connection with the Company’s annual and interim
consolidated financial statements required under the laws of any other relevant
jurisdiction, through Price Waterhouse & Co. S.R.L.) as the Company’s
independent auditors for the fiscal year ending December 31, 2009, to be engaged
until the next annual general meeting that will be convened to resolve on the
2009 accounts.
The Meeting also approved the
independent auditors’ fees for
audit, audit-related and other services to be rendered during the fiscal year
ending December 31, 2009, broken-down into four currencies (Argentine Pesos,
Euro, Mexican Pesos, and U.S. Dollars), up to a maximum amount for each currency
equal to ARS 5,163,342.00; EUR 70,900.00; MXN 11,232,744.00 and USD 183,821.00,
and authorized the audit committee of the Board of Directors to approve any
increase or reallocation of the independent auditors’ fees as may be necessary,
appropriate or desirable under the circumstances.
8) Authorization
to the Board of Directors to delegate the day-to-day management of the Company’s
business to one or more of its members.
The
Meeting resolved to authorize the Board of Directors to delegate the management
of the Company’s day-to-day business and the authority to represent and bind the
Company with his sole signature in such day-to-day management to Mr. Daniel
Agustin Novegil, and to appoint Mr. Novegil as chief executive officer
(administrateur délégué) of the Company.
9) Authorization
to the Board of Directors to appoint one or more of its members as the Company’s
attorney-in-fact.
The
Meeting resolved to authorize the Board of Directors to appoint any or all
members of the Board of Directors from time to time as the Company’s
attorney-in-fact, and to delegate to such directors any management powers
(including, without limitation, any day-to-day management powers) to the extent
the Board of Directors may deem appropriate in connection therewith, this
authorization to be valid until expressly revoked by the Company’s general
shareholders meeting.
10) Authorization
to the Board of Directors of the Company or the board of directors or other
governing bodies of the Company’s subsidiaries to acquire shares of the
Company.
The
Meeting resolved to authorize the Company and the Company’s subsidiaries to
acquire shares of the Company, including shares represented by ADRs, at such
times and on such other terms and conditions as may be determined by the board
of directors of the Company or the board of directors or other governing body of
the relevant Company subsidiary, provided that, among other
conditions, the nominal value of the shares so acquired, together
with shares previously acquired by the Company, the Company’s wholly-owned
subsidiaries or any other person acting on the Company’s behalf, and not
cancelled, shall not exceed 10% of the Company’s issued and outstanding shares
or, in the case of acquisitions of shares made through a stock exchange in which
the shares or ADRs are traded, such lower amount as may not be exceeded pursuant
to any applicable laws or regulations of such market, and that the purchase
price per ADR to be paid in cash may not exceed 125% (excluding transaction
costs and expenses), nor may it be lower than 75% (excluding transaction costs
and expenses), in each case of the average of the closing prices of the ADRs in
the New York Stock Exchange during the five trading days in which transactions
in the ADRs were recorded in the New York Stock Exchange preceding (but
excluding) the day on which the ADRs are purchased and, in the case of purchases
of shares other than in the form of ADRs, the per share purchase price may not
exceed the maximum nor may it be lower than the minimum purchase prices that
would have applied in case of an ADR purchase divided by the number of
underlying shares represented by an ADR at the time of the relevant purchase. In
addition, the acquisitions of shares or ADRs carried out pursuant to this
authorization shall be made on the other terms and subject to the other
conditions described in the relevant item of the Shareholder Meeting Brochure
and Proxy Statement submitted to the U.S. Securities and Exchange Commission on
Form 6-K on May 5, 2009 (available through http://www.sec.gov/), and shall
comply with the relevant provisions of he Luxembourg law of August 10, 1915 on
commercial companies and, where applicable, with the laws and regulations of the
markets where the shares or other securities representing shares are
traded.